TRANSCATHETER MITRAL VALVE REPLACEMENT MARKET :TRENDS ANALYSIS AND FORECASTS UP TO 2022
The Transcatheter mitral valve replacement Market,
also known as the bicuspid valve or left atrio-
ventricular valve, is a dual-flap valve in the heart that
lies between the left atrium and the left ventricle. The
mitral valve and the tricuspid valve are known collec-
tively as the atrio-ventricular valves because they lie
between the atria and the ventricles of the heart. The
mitral valve manages blood flow between left atrium
and left ventricle; and prevents backward flow of the
blood into left atrium. Mitral regurgitation is leakage of
blood backward through the mitral valve each time
the left ventricle contracts. This is a most common
mitral valve disorder that causes abnormal blood
flow. As a remedy for this problem, surgeons use mi-
tral surgical vale repair procedures or transcatheter
replacement methods.
Some of the key driving factors attributing to the
growth of this market include increasing number of
patients with mitral valve disorders. Approximately 7
million people in the U.S., suffer from mitral regurgita-
tion in the U.S., and they represent almost 2% of the
nations population. Similarly, approximately the
same number of people suffer from the condition in
Europe. This group includes 4.1 million people who
have moderate to severe mitral regurgitation. The
number of new patients suffering with mitral regurgi-
tation disease added each year is 250,000. Among
this 4.1 million patients, only about 20% or 1.67 mil-
lion are eligible for the treatment. This creates huge
opportunity for the global transcatheter mitral valve
replacement market.
In addition, increasing adoption of minimally invasive
procedures over traditional surgical open heart proce-
dures, reduction in hospital stays, low risk of infec-
tion, minimal blood loss are further propelling the
market. According to World Health Organization
(WHO), it has been estimated that the number of
people suffering from cardiovascular diseases will
increase to 22.2 million by 2030. The market for
TMVR is expected to reach around USD 3.0 billion by
2022, growing at a CAGR of 15.9% during the fore-
cast period of 2016e to 2022f. However, there are
certain restraining factors which could hamper the
growth of this market, which includes, high costs as-
sociated with the LMVD implantation compared to
other therapies available for CVD diseases.
Geographically, North America is leading contributor
to the market and is expected to retain its position
during the forecast period. Nonetheless, the market
for Asia-Pacific region is expected to grow at a faster
rate owing to increasing prevalence of CVD diseases,
growing awareness about minimally invasive surgical
procedures among the population, improving
healthcare infrastructure, rise in healthcare spending,
and favorable government policies.
Companies profiled:
Edwards Lifesciences Corp.
Abbott Laboratories
Medtronic
Micro Interventional Devices
Sinomed
To purchase complete report on Transcatheter mitral valve replacement (TMVR) Market visit:

URL: https://www.infiniumglobalresearch.com/reports/transcatheter-mitral-valve-replacement-
tmvr-market

website : www.infiniumglobalresearch.com

Contact us:

Email sales@infiniumglobalresearch.com

Skypeid: infiniumglobalresearch